Christopher D. Brown - 13 Jun 2025 Form 3 Insider Report for 908 Devices Inc. (MASS)

Role
Director
Signature
/s/ Michael S. Turner, as Attorney-in-Fact
Issuer symbol
MASS
Transactions as of
13 Jun 2025
Net transactions value
$0
Form type
3
Filing time
18 Jun 2025, 16:37:18 UTC
Previous filing
04 Feb 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Brown Christopher D. Director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON /s/ Michael S. Turner, as Attorney-in-Fact 18 Jun 2025 0001836988

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MASS Common Stock 962,122 13 Jun 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MASS Stock Option (option to buy) 13 Jun 2025 Common Stock 114,318 $1.75 Direct F1
holding MASS Stock Option (option to buy) 13 Jun 2025 Common Stock 67,604 $3.24 Direct F1
holding MASS Stock Option (option to buy) 13 Jun 2025 Common Stock 33,400 $16.66 Direct F2
holding MASS Stock Option (option to buy) 13 Jun 2025 Common Stock 45,018 $8.83 Direct F3
holding MASS Stock Option (option to buy) 13 Jun 2025 Common Stock 60,064 $7.35 Direct F4
holding MASS Restricted Stock Units 13 Jun 2025 Common Stock 5,027 Direct F5, F6
holding MASS Restricted Stock Units 13 Jun 2025 Common Stock 14,836 Direct F5, F7
holding MASS Restricted Stock Units 13 Jun 2025 Common Stock 32,974 Direct F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option are fully vested and immediately exercisable.
F2 Twenty-five percent of the shares underlying the option become vested and exercisable on February 1, 2023, and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 1, 2023, subject to the reporting person's continued service through the applicable vesting date.
F3 Twenty-five percent of the shares underlying the option become vested and exercisable on February 1, 2024, and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
F4 Twenty-five percent of the shares underlying the option become vested and exercisable on February 1, 2025, and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 1, 2025, subject to the reporting person's continued service through the applicable vesting date.
F5 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date.
F6 These RSUs vest in four substantially equal annual installments at the four anniversary dates following February 1, 2022, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date.
F7 These RSUs vest in four substantially equal annual installments at the four anniversary dates following February 1, 2023, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date.
F8 These RSUs vest in four substantially equal annual installments at the four anniversary dates following February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date.